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Summary: Patients with peripheral arterial disease (PAD) are at very high risk of cardiovascular events, but risk factor
management is usually suboptimal. This Joint Task Force from the European Atherosclerosis Society and the European
Society of Vascular Medicine has updated evidence on the management on dyslipidaemia and thrombotic factors in patients
with PAD. Guidelines recommend a low-density lipoprotein cholesterol (LDLC) goal of more than 50% reduction from baseline
and <1.4 mmol/L (<55 mg/dL) in PAD patients. As demonstrated by randomized controlled trials, lowering LDL-C not only
reduces cardiovascular events but also major adverse limb events (MALE), including amputations, of the order of 25%.
Addition of ezetimibe or a PCSK9 inhibitor further decreases the risk of cardiovascular events, and PCSK9 inhibition has also
been associated with reduction in the risk of MALE by up to 40%. Furthermore, statin- based treatment improved walking
performance, including maximum walking distance, and pain-free walking distance and duration. This Task Force
recommends strategies for managing statin-associated muscle symptoms to ensure that PAD patients benefit from lipid-
lowering therapy. Antiplatelet therapy, either daily clopidogrel 75 mg or the combination of aspirin 100 mg and rivaroxaban
(22.5 mg) is also indicated to prevent cardiovascular events. Dual pathway inhibition (aspirin and rivaroxaban) may be
considered following revascularization, taking into account bleeding risk. This Joint Task Force believes that adherence with
these recommendations for lipid-lowering and antithrombotic therapy will improve the morbidity and mortality in patients
with PAD.
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Peripheral arterial disease (PAD), characterised by
atherosclerosis in the arteries of the lower limb, poses an
increasing health and societal burden world-wide. Already
affecting more than 20% of individuals aged over 60 years
[1 2], the prevalence will escalate as the population ages.
This is highly relevant given that cardiovascular risk is
higher among PAD patients than those with coronary artery
disease (CAD) alone and increases with disease severity
(Figure 1) [3, 4, 5]. Five-year mortality with PAD is almost
double that of CAD (25% versus 13%) and higher than for
many cancers, equating almost exactly to Duke’s stage B
carcinoma of colon [3, 6, 7]. Despite recognition of this
high attrition rate, however, mortality associated with
PAD has essentially remained unchanged over the past
25 years (Figure 2) [3, 8], unlike the decline evident for
CAD [3, 9, 10]. This poor prognosis can be largely attributed
to sub-optimal management of cardiovascular risk factors
[9], as recommended by evidence-based guidelines
[11, 12, 13].
Although PAD and CAD are both caused by atheroscle-
rosis and share common lesion features, the clinical course,
therapeutic response and certain demographic features
suggest that there are factors that make PAD subjects more
susceptible to the clinical manifestations of atherosclerosis
[14]. PAD is characterised by higher levels of systemic
inflammation markers, and a higher prevalence of diabetes
than CAD [15]. As for all phenotypes of atherosclerosis,
dyslipidaemia is one of the most important modifiable
cardiovascular risk factors in PAD [16].
The European Society of Vascular Medicine (ESVM) and
the European Atherosclerosis Society (EAS) recognise the
need for a renewed focus on the management of PAD. This
Joint Statement provides clear and updated evidence-based
consensus on the management on dyslipidaemia and
thrombotic factors, with the aim of decreasing the appalling
cardiovascular morbidity and mortality associated with
PAD.
Lipid-lowering therapies in PAD
What is the evidence that elevated lipids
and lipoproteins increase risk for PAD?
Despite controversy over the years, elevated lipids are now
known to be associated with increased cardiovascular risk
in PAD [16]. Indeed, in a previous report, a discordant lipid
profile was reported in patientswith PADcompared to unaf-
fected controls [17]. As with all phenotypes of atherosclero-
sis, apolipoprotein (apo)B-containing lipoproteins, which
include all lipoproteins except high-density lipoproteins
(HDL), are key players driving the initiation and progression
of disease [18]. The archetypal apoB-containing lipoprotein
is low-density lipoprotein (LDL), which is established as
causal for atherosclerotic cardiovascular disease (ASCVD)
[19, 20]. There is also accumulating evidence to suggest a
causal role for triglyceride-rich lipoproteins and their
remnant particles in atherosclerosis [21].
ApoB-containing lipoproteins retained in the arterial wall
initiate the atherosclerotic process [18]. Higher levels of
apoB-containing lipoproteins in plasma promote the
development and progression of atherosclerotic plaques.
Hence, the concentration and total duration exposure of
apoB-containing lipoproteins, together with the concentra-
tion of circulating LDL cholesterol (LDL-C), represent the
overall atherosclerotic plaque burden of an individual
person [22, 23].
An increased ratio of apoB/apoAI (the apolipoprotein in
HDL) was predictive of PAD risk in middle aged healthy
men [24]. Genetic and epidemiologic studies provide
insights into the role of specific apoB-containing lipopro-
teins that determine this risk. A genome-wide association
study including over 30,000 PAD patients and 210,000
controls of the Million Veteran Program (MVP) identified
variants in the genes encoding the LDL receptor (LDLR),
lipoprotein lipase (LPL), and lipoprotein(a) [Lp(a)] (LPA)
as drivers of PAD [25]. Interestingly, in replication analyses
inmore than 5,000 PAD patients from the UK Biobank, the
LPA variant was the top locus associated with PAD. This
finding is supported by an epidemiologic study showing a
dose-dependent association of Lp(a) molar concentration
and PAD [26].
The MVP study also identified several variants that were
associated with either hypercholesterolaemia or hyper-
triglyceridaemia and PAD [25]. These findings are impor-
tant as epidemiologic support for an association between
elevated LDL-C concentration and PAD is less consistent
than for CAD. For example, in the Health Professionals
Follow-up Study, hypercholesterolaemia contributed 17%
of the PAD risk [27]. Furthermore, associations of total
cholesterol levels, total cholesterol/HDL ratio, and triglyc-
eride concentration with PAD were often attenuated or
abrogated after multivariate adjustment [28]. More
recently, a prospective study of more than 27,000 women
without incident PAD found that elevated LDL-particle
number (based on nuclear magnetic resonance measure-
ment) and triglyceride-rich lipoproteins but not LDL-C
concentration were associated with PAD risk [29].
While some uncertainties persist regarding the contribu-
tion of individual apoB-containing lipoproteins to the
different clinical manifestations of atherosclerosis, particu-
larly in symptomatic PAD, overwhelming evidence sup-
ports the collective role of these lipoproteins in driving
PAD. Moreover, as LDL-C is unequivocally established as
causal for ASCVD [19], it is therefore the primary target
when treating dyslipidaemia in patients with PAD [30].
What are the lipid goals in PAD?
The 2019 European Society of Cardiology/EAS dyslipi-
daemia guidelines recommend LDL-C goals according to
the 10-year risk for fatal cardiovascular events. Patients
with PAD belong in the very high-risk category, with
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10% risk of a fatal cardiovascular event. In these patients,
both LDL-C reduction by 50% from baseline and an
LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recom-
mended [30].
To attain this LDL-C goal treatment with a high-intensity
statin at the maximal tolerated dose is recommended. If
patients are unable to attain goal or report statin intoler-
ance, a combination of statin (at a lower dose if statin intol-
erant) with ezetimibe is recommended, with addition of a
PCSK9 (proprotein convertase subtilisin/kexin type 9) inhi-
bitor if further LDL-C lowering is indicated [31]. Lipid
levels should be monitored 8 (±4) weeks after starting or
adjusting treatment until LDL-C goal is achieved, and
thereafter at least annually or as indicated.
Despite guideline recommendations, however, PAD
patients are often underdiagnosed and inadequately man-
aged compared with CAD patients, both for lifestyle inter-
vention and pharmacotherapy [32]. As with other very
A
B
Figure 2. Little change in PAD patient survival over the last 25 years. Comparison of 10-year survival (A) between 1978 and 1990 (modified from
Criqui et al. [10]) and (B) between 2003 and 2015 (according to cause of death) (modified from Sartipy et al. [3]).
Figure 1. Comparison of 5-year mortality rates: PAD versus common cancers.
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high-risk groups, registries show disappointing results in
terms of adherence with lifestyle and LDL-C goal achieve-
ment. In a study of symptomatic PAD patients, less than
three-quarters did not attain an LDL-C level below 1.8
mmol/L (70 mg/dL) and nearly half had LDL-C levels
above 2.5mmol/L (100mg/dL) [33]. Similar findings were
reported among PAD patients included in studies of high
cardiovascular risk populations [34, 35].
What is the evidence that lipid-lowering
therapy improves outcome in PAD?
While lipid-lowering therapy indisputably reduces cardio-
vascular events in patients with CAD, evidence from
prospective well-powered studies in PAD patients is more
limited. In a systematic review of 18 trials of different
lipid-lowering agents in 10,000 patients with lower limb
PAD, lowering LDL-C concentration was associated with
20% reduction in total cardiovascular events and improve-
ments in total walking distance and pain-free walking
distance, but not ankle brachial index (ABI) [36]. Evidence
for individual lipid-lowering therapies is summarizedbelow.
Statins
Statins are guideline-recommended first line lipid-lowering
therapy in patients with PAD, supported by definitive evi-
dence of cardiovascular morbidity and mortality benefits
[12, 37, 38]. Furthermore, there is also support for positive
effects of lipid-lowering on major adverse limb events
(MALE), as well as walking performance in patients with
PAD.
Major adverse cardiovascular events (MACE)
and MALE
There is clear evidence that statin treatment substantially
improves cardiovascular outcomes and MALE in PAD
patients.Onemeta-analysis evaluated 51 studies (2 random-
ized controlled trials, 20 prospective studies, and 29 retro-
spective studies) in 138,060 PAD patients with either
stable claudication, critical limb ischaemia (CLI) or under-
going lower extremity revascularization, of whom 35%
received a statin [39].MACE included all-cause death, com-
posite cardiovascular endpoints, cardiovascular death and
stroke, and MALE included amputation and graft occlu-
sion/revascularization. Statin treatment not only reduced
all-cause mortality by 39%, cardiovascular death by 41%,
cardiovascular outcomes by 34% and ischaemic stroke by
28%, but also reduced MALE by 30% and amputations by
35% (Table I). Another meta-analysis of 19 studies in
26,985 patients with CLI, about half on a statin, showed
25% reduction in amputation and 38% reduction in fatal
events. Statin therapy was also associated with improved
overall patency rates and lower incidence of MACE [40].
To some extent findings from these meta-analyses are
confounded by inclusion of retrospective studies, as well
as the fact that generally less than half of these patients
were on a statin. To address these issues, this Joint Task
Force conducted a meta-analysis of randomized controlled
trials of statin-based treatment identified by MEDLINE
searches which reported major cardiovascular events,
cardiovascular mortality, or all-cause mortality in PAD
patients [41, 42, 43, 44, 45]. Estimates for between group
differences (statin vs. control) were derived using both
fixed-effects (Mantel & Haenszel method) [46] and
random-effects models (DerSimonian & Laird method)
[47], with the latter reported if there was significant hetero-
geneity. Overall, this analysis showed that statin treatment
reduced MACE by 24% (odds ratio 0.76, 95% confidence
interval [CI] 0.69–0.83), cardiovascular death by 17%
(odds ratio 0.83, 95% CI: 0.26–2.60) and all-cause mortal-
ity by 18% (odds ratio 0.82, 95% CI: 0.69–0.97) (Figure 3).
Outcome after limb intervention
There are limited data for the effect of statin treatment on
outcomes after surgical and endovascular procedures.
Pooled analysis of seven studies in patients with CLI, did,
however, indicate that statin treatment was associated with
lower rates of loss of patency (hazard ratio: 0.80, 95% CI:
0.66–0.96) [40].
Claudication development
There is some evidence that statin treatment can decrease
the development and progression of PAD. For example,
analyses from the Scandinavian Simvastatin Survival Study
(4S), showed that cholesterol lowering with simvastatin
reduced the incidence of carotid bruits and cerebrovascular
events, as well as new-onset or worsening of angina
pectoris and intermittent claudication [48]. The authors
concluded that simvastatin may have a general anti-ather-
osclerotic effect not limited to the coronary bed. More
recently, investigation of atheroma burden using serial
whole body magnetic resonance angiography over 3 years
showed that individuals with atheroma progression at
Table I. Effect of statin treatment on cardiovascular and major adverse limb events in patients with peripheral arterial disease
Outcome Relative risk reduction (%) Hazard ratio (95% CI)
Composite cardiovascular events 34 0.662 (0.59–0.741)
Cardiovascular death 41 0.594 (0.455–0.777)
All-cause death 39 0.608 (0.543–0.680)
Major adverse limb events 30 0.702 (0.605–0.815)
Amputation 35 0.654 (0.522–0.819)
Results from a meta-analysis of 51 studies in 138,060 patients, 35% treated with a statin. Derived from Pastori et al. [39].
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follow-up were less likely to be on statin therapy (79% vs.
100%, p=0.04), and had a significantly higher baseline
atheroma score (17.6±11.2 vs. 10.7±5.1, p=0.043) [49].
Walking performance
Statin treatment was also shown to favourably impact walk-
ing performance in PAD patients with claudication. In one
meta-analysis, maximal walking distance for patients on
lipid-lowering therapy, notably statins, improvedmore than
that reported with vasodilators, phosphodiesterase and
platelet inhibitors (increase by 150 vs. 50metres) [50]. This
benefit increased over time with maximal effect after
several months of treatment but was not accompanied by
improvement in ABI measurement. Another study showed
no difference between patients with claudication doing
exercise training treated with atorvastatin versus control,
suggesting no added benefit from statin treatment [51].
The effects of statin-based treatment on walking perfor-
mance were further investigated in the meta-analysis
conducted by this Joint Task Force [41, 42, 45, 51, 52].
Two outcomes were evaluated: maximal walking distance
and free-pain walking (both duration and distance) on a
treadmill. Based on the random-effects model, statin treat-
ment improved walking distance by 45 metres (95% CI:
64.7 to 154.7 metres). There was also improvement in
pain-free walking distance and duration (by 15.3 metres





Figure 3. Effect of statin-based treatment on the risk of cardiovascular outcomes and all-cause mortality in patients with PAD. Meta-analysis of
randomized controlled trials of statin therapy, showing the effects of statin-based treatment on risk for MACE (A), cardiovascular death (B) and
all-cause mortality (C). Analyses based on data in Castano et al. [41], Mohler et al. [42], Heart Protection Study Collaborative Group et al. [43],
Ramos et al. [44] and Aronow et al. [45]. (A) Effect of statin-based treatment on risk for MACE. (B) Effect of statin-based treatment on risk of
cardiovascular death. (C) Effect of statin-based treatment on risk of all-cause mortality.
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Combination treatment with statin
and ezetimibe
Guidelines recommend the addition of ezetimibe if very
high-risk patients fail to attain LDL-C goal with maximally
tolerated statin therapy. The cardiovascular benefits of
this combination therapy is supported by results from
IMPROVE-IT (IMProved Reduction of Outcomes:Vytorin
Efficacy International Trial), in which ezetimibe on top of
simvastatin therapy significantly reduced cardiovascular
events (a composite of cardiovascular death, myocardial
infarction, unstable angina requiring rehospitalization,
coronary revascularization or non-fatal stroke) in patients
with ACS (hazard ratio: 0.936; 95% CI: 0.89–0.99;
p=0.016) [53]. Subgroup analyses investigated the effects
of this combination treatment in patients with poly-
vascular disease; 1005 (6%) had PAD and 1071 (6%) had
stroke or transient ischaemic attack at baseline, with con-
comitant type 2 diabetes in over one-third [54]. Patients
with polyvascular disease were at higher risk, with 7-year
Kaplan-Meier cardiovascular event rates 39.8% and
60.0% with concomitant type 2 diabetes versus 29.6% in
those with ACS alone.
Although the relative risk reduction associated with
ezetimibe plus simvastatin was consistent in patients with
or without concomitant polyvascular disease, the absolute
benefit was substantially higher in patients with polyvascu-
lar disease, especially those with concomitant type 2
diabetes (absolute risk reductions 4.2% and 9.1% vs. 1.7%
in those with ACS alone). These translated to a number
needed to treat to prevent one event of 24 in patients with
polyvascular disease and 11 with concomitant type 2
diabetes versus 59 in those with ACS alone [54]. These
findings reinforce the greater cardiovascular benefit from
further LDL-C lowering with the combination of ezetimibe
and simvastatin.
Combination treatment with statin
and a PCSK9 inhibitor
Monoclonal antibodies against PCSK9, i.e., evolocumab
and alirocumab, are highly efficacious treatments that
reduce LDL-C by 60% on top of statin therapy and are
associated with significant reduction in cardiovascular
events in outcomes studies in very high-risk populations
[55, 56]. Prespecified analyses of these trials have also
demonstrated cardiovascular and limb benefit in PAD
patients.
What is the evidence that PCSK9 inhibitors, on top
of statins, improve outcome in PAD patients?
The FOURIER trial (Further Cardiovascular Outcomes
Research with PCSK9 Inhibition in Subjects with Elevated
Risk) trial investigated treatment with evolocumab against
a background of intense statin therapy (with or without eze-
timibe) in 27,564 patients with coronary, cerebrovascular,
or peripheral arterial atherosclerosis [55]. A prespecified
analysis included 3,642 patients with confirmed lower limb
PAD, identified by intermittent claudication and an ABI
<0.85, or with a prior peripheral vascular procedure [57].
At the time of randomization, 57% of patients had a history
of peripheral revascularization, 3% had undergone ampu-
tation, and 69%had an ABI <0.85 and claudication. Almost
all were on a statin and 89%were also on antiplatelet ther-
apy. These patients were at higher absolute risk of both
MACE and MALE when compared with those with
atherosclerosis affecting other vascular beds. Treatment
with evolocumab significantly reduced the primary end
point (a composite of cardiovascular death, myocardial
infarction, stroke, hospitalization for unstable angina, or
coronary revascularization) by 21%, as well as the risk of
MALE by 42% [57]. Thus, FOURIER was the first random-
ized trial to demonstrate that intensive LDL-C lowering
decreases the risk of MALE with no safety concerns.
Subsequent analyses of the ODYSSEY OUTCOMES
study in 18,924 patients with recent acute coronary
syndrome provides further insights [56]. Patients were
randomized to alirocumab on top of maximally tolerated
statin or statin alone. In those patients who also had PAD
(3.2%of the total study population), treatment with alirocu-
mab was associated with 7% reduction in relative risk for
the primary endpoint (a composite of coronary heart
disease death, nonfatal myocardial infarction, fatal or
nonfatal ischaemic stroke, or unstable angina requiring
hospitalization) [58]. In patients with atherosclerosis in
three vascular territories, the relative risk reduction was
substantially higher (by 36% versus 15% for the overall
study population) [58]. In a subsequent analysis including
all patients with a history of PAD, treatment with alirocu-
mab significantly reduced the risk for PAD events (a com-
posite of critical limb ischaemia, limb revascularization,
and amputation for ischaemia) by 41%, corresponding to
an 8.6% absolute reduction in risk at 3 years. Notably,
the ODYSSEY OUTCOMES Study Investigators identi-
fied baseline Lp(a) but not LDL-C concentration as a pre-
dictor of the reduction in risk for PAD events with
alirocumab [59].
Finally, combined analysis of both trials conducted by
this Joint Task Force showed that treatment with a PCSK9
inhibitor, on top of maximally tolerated statin therapy, was
associated with a significant 24% reduction in cardiovascu-
lar events (odds ratio 0.76, 95% CI: 0.64–0.91), although
the difference in all-cause mortality did not achieve
statistical significance (odds ratio 0.85, 95% CI: 0.67–
1.09) [57, 58].
How to manage muscle adverse effects
with statins
Beyond efficacy, the adverse effects of statin therapy,
notably perceived or reported muscle pain and cramping,
merit consideration in the setting of PAD, given their
potential detrimental impact on treatment compliance.
Statin associated muscle symptoms (often referred to as
SAMS) cover a broad range of clinical presentations,
including pain or itching, stiffness, tenderness or cramping,
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and may affect about 15–20% of patients, more frequently
women than men [60, 61]. Clinical presentation of muscle
symptoms is highly heterogenous, although muscle pain
and weakness are usually symmetrical and proximal and
affect large muscle groups including the thigh, buttock,
calves, and back muscles, typically occurring 4–6 weeks
after starting treatment [62]. The risk of muscle pain with
statins is increased in patients aged over 80 years, as well
as those with a smaller body frame, excessive alcohol
intake, or hypothyroidism. The onset of new symptoms
may occur with an increase in statin dose or after initiation
of an interacting drug [63]. People who have exercised reg-
ularly before taking statins are less likely to experience
muscle pain.
The underlying mechanisms of muscle pain in statin
users are not completely elucidated. Preclinical studies
showed that statins decreasemitochondrial function, atten-
uate energy production and alter muscle protein degrada-
tion. Additionally, statins cause spontaneous and irregular
leaks of calcium from storage within muscle cells and pro-
voke muscle contraction; unregulated calcium leak may
also cause damage to muscle cells leading to muscle pain
and weakness [64].
SAMS significantly contribute to very high discontinua-
tion rates of statin therapy (up to 75%) [65]. Anecdotally,
this proportionally affects many patients with PAD who
already have muscle problems in the legs. Treatment
non-adherence may have a marked impact on the cardio-
vascular benefits of statin treatment. In one meta-analysis,
patients who were adherent to statin treatment had a 15%
lower risk of cardiovascular events compared with those
with low adherence [66]. To overcome SAMS, the use of
an alternative statin which is metabolised via different
hepatic cytochromes is generally recommended, for exam-
ple the use of rosuvastatin instead of atorvastatin or sim-
vastatin or vice versa.
SAMS are manageable; studies indicate that 90% of
patients reporting muscle symptoms are able to tolerate
an alternative statin [67]. Another recommended approach
is the combination of the maximally tolerated statin dose
and a non-statin lipid-lowering therapy such as ezetimibe
to attain LDL-C goal.
Conclusions
Taken together, the available literature shows that patients
with PAD are at very high cardiovascular risk and should be
targeted to achieve guideline-recommended LDL-C goal.
Statin-based treatment has been shown to substantially
reduce the risk of MACE and MALE by about 25%. The
addition of a PCSK9 inhibitor further decreases this risk.
Statin-based treatment has also been associated with
improved walking performance, including maximum walk-
ing distance, and pain-free walking distance and duration.
Perceived or reported muscle symptoms should be
assessed and every effort made to ensure that the patients
remain on lipid-lowering therapy. Recommended strate-
gies include the use of a lower statin dose combined with
a non-statin lipid-lowering therapy such as ezetimibe to
attain LDL-C goal.
Antithrombotic therapies in PAD
What can we learn from genetic studies?
Patients with PAD are at high risk of MACE andMALE due
to underlying atherothrombotic disease. Genetic studies
provide novel insights into thrombotic factors associated
with this risk. A genome-wide association study of PAD
patients and controls of the MVP (discussed previously)
identified a new PAD risk variant in Factor V (Factor V
Leiden) that was uniquely associated with PAD, but not
other vascular beds. The association of this variant with
PAD risk increased with disease severity and was highest
with PAD related amputation (odds ratio 1.62) [25]. Given
that Factor V Leiden is the most common cause for inher-
ited thrombophilia, this finding underlines the prominent
role of thrombosis in the pathogenesis of PAD. Another
study showed that CLI in PAD patients was associated with
thrombotic luminal occlusion in the absence of advanced
atherosclerosis [68]. Furthermore, the close functional
relationship between Factor V and Factor Xa in the coagu-
lation cascade supports preventive approaches targeting
Factor Xa, as illustrated by the COMPASS trial with the
combination of low-dose rivaroxaban and aspirin versus
aspirin alone [69].
What is the evidence that antithrombotic
therapy reduces MACE and MALE in PAD?
Current management of symptomatic PAD includes anti-
platelet monotherapy (either aspirin 75–100 mg daily or
clopidogrel 75 mg daily), with improved benefit from more
intense antiplatelet therapy [12, 70, 71]. The Antithrom-
botic Trialist Collaboration study in 6,200 patients with
intermittent claudication demonstrated significant reduc-
tion in MACE with antiplatelet therapy (most commonly
aspirin) versus control (6.4% vs. 7.9%) [72]. A subsequent
post hoc analysis of the CAPRIE trial (n=6,452) showed that
clopidogrel was superior to aspirin in patients with clinical
PAD, with significant reductions in cardiovascular mortal-
ity (hazard ratio: 0.76, 95% CI: 0.64–0.91) and MACE
(hazard ratio: 0.78, 95% CI: 0.65–0.93) [73]. Although a
post hoc analysis of 3,906 asymptomatic and symptomatic
PAD patients included in the CHARISMA trial indicated
reduction in myocardial infarction with both aspirin and
clopidogrel vs. aspirin monotherapy (hazard ratio: 0.63,
95% CI: 0.42–0.95), this was also associated with a signif-
icantly increased risk of bleeding (hazard ratio: 1.99, 95%
CI: 1.69–2.34) [74].
Following below-the-knee bypass grafting, dual antipla-
telet therapy (DAPT) was shown to reduce the primary
efficacy endpoints (composite of index-graft occlusion or
revascularization, above-ankle amputation of the affected
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limb, or death) in patients receiving a prosthetic but not
venous graft [75]. In patients with stent implantation, pro-
longed DAPT should be considered with a recent acute
coronary syndrome and/or percutaneous coronary inter-
vention (<1 year), stenting of the last patent coronary
artery, and multiple coronary vessel disease in diabetes
patients with incomplete revascularization. In support, the
PRODIGY trial demonstrated benefit with prolonged
DAPT (24 months vs. 6 months) after acute coronary syn-
drome only in patients with concomitant PAD (hazard
ratio: 0.54, 95% CI: 0.31–0.95) [76]. Additionally, the
PEGASUS-TIMI 54 trial demonstrated that DAPT (tica-
grelor plus aspirin) in stable patients with prior myocardial
infarction (1–3 years) significantly reduced the risk of
MALE (acute limb ischaemia and peripheral revasculariza-
tion) in a subgroup of patients with PAD (hazard ratio:0.65,
95% CI: 0.44–0.95) [77].
While plasma coagulation is also implicated as a contrib-
utor to peripheral events, trials of therapeutic anticoagula-
tion using vitamin K antagonists in PAD patients showed
little benefit and caused increased bleeding. Inhibition of
thrombin generation with a low dose Factor Xa inhibitor
added to antiplatelet therapy can reduce ischaemic risk,
as demonstrated by the COMPASS trial in patients with
stable CAD or PAD [69, 78]. The combination of rivaroxa-
ban 2.5 mg twice daily and aspirin 100 mg once daily
reduced the risk of MACE by 28% (hazard ratio: 0.72,
95% CI: 0.57–0.90), as well as limb events, including
MALE by 46% (hazard ratio: 0.54, 95% CI: 0.35–0.84),
acute limb ischaemia by 44% (hazard ratio: 0.56, 95%
CI: 0.32–0.99), and MALE plus major amputation by
46% (hazard ratio: 0.54, 95% CI: 0.35–0.82). There was,
however, an increase in major bleeding but not fatal or crit-
ical organ bleeding (hazard ratio: 1.61, 95% CI: 1.12–2.31).
Thus, the COMPASS trial demonstrated for the first time
that antithrombotic treatment in patients with PAD reduces
both MACE and MALE, including amputation, although at
the risk of increased bleeding [79].
Finally, VOYAGER PAD compared rivaroxaban 2.5 mg
twice daily plus aspirin and aspirin alone in 6,564 PAD
patients who had undergone lower-extremity revascular-
ization [80]. The primary efficacy outcome was a compos-
ite of acute limb ischaemia, major amputation for vascular
causes, myocardial infarction, ischaemic stroke or cardio-
vascular death. Three-year Kaplan-Meier estimates
showed a significant 15% reduction in the primary outcome
in the rivaroxaban group (17.3% vs. 19.9% with placebo,
hazard ratio: 0.85, 95% CI: 0.76–0.96; p =0.009). The
absolute risk reduction was 1.5% at 6 months, 2.0% at
one year and 2.6% at 3 years. While TIMI major bleeding
did not differ significantly between the groups, the inci-
dence of ISTH (International Society on Thrombosis and
Haemostasis) major bleeding was significantly higher with
rivaroxaban and aspirin than with aspirin alone. It was
Figure 4. Recommendations of the European Atherosclerosis Society/European Society of Vascular Medicine Task Force for the management of
PAD patients.
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estimated that for every 10,000 patients treated for one
year, rivaroxaban 2.5mg twice daily added to aspirin would
prevent 181 primary efficacy outcome events at the cost of
29 principal safety outcome events [80].
Taken together, the results from the VOYAGER PAD
trial complement and extend findings from the COMPASS
trial. Thus, for patients with extensive PAD, especially
those who have undergone revascularization for PAD,
addition of rivaroxaban to the treatment regimen may be
considered weighing concomitantly the bleeding risk.
Key recommendations
Based on the evidence discussed in this statement, this
Joint EAS-ESVM Task Force provides recommendations
for the management of PAD patients (Figure 4). Optimal
management of dyslipidaemia, together with guideline
recommended antithrombotic therapy, are essential to
improve the morbidity, disability and mortality of this
increasingly prevalent – but underdiagnosed and under-
treated – condition.
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